Joseph M. Tibaldi

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

Thyrotoxicosis in the very old

Joseph M. Tibaldi, Uriel S. Barzel, Joan Albin et al. · The American Journal of Medicine · 1986 · 92 citations

Medicine, Endocrinology, Geriatric Medicine +6

A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin‐naïve patients with type 2 diabetes

Joseph M. Tibaldi, Martin Hadley‐Brown, Andreas Liebl et al. · Diabetes Obesity and Metabolism · 2018 · 47 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Practical guidance on intensification of insulin therapy with BIAsp 30: a consensus statement

AG Unnikrishnan, Joseph M. Tibaldi, Martin Hadley‐Brown et al. · International Journal of Clinical Practice · 2009 · 40 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +14